Drugs / JMT601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06725524 | Oct 2021 → Dec 2025 overdue | B-cell non-Hodgkin lymphoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07029139 | Jun 2025 → Apr 2027 expected | idiopathic membranous glomerulonephritis | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-01-27 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - JMT601 (CPO107) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that JMT601 (CPO107), a first-in-class drug candidate developed by the Group, has been granted Fast Track Designation by the U.S. Food and Drug Administration (“FDA”) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. |
| 2021-03-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2021-03-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗
The board of directors (the “ Board”) of CSPC Pharmaceutical Group Limited (the “ Company ”, together with its subsidiaries, the “Group”) is pleased to announce that JMT601, a first-in-class drug candidate developed by Shanghai JMT-BIO Technology Co., Ltd.* ʮ̡ (“Shanghai JMT-BIO ”), a subsidiary of the Company, has obtained approval of its investigational new drug (IND) application from the National Medical Products Administration (NMPA) to initiate clinical trial for Non-Hodgkin lymphoma (NHL). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-01-27 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - JMT601 (CPO107) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA irasia.com ↗ |
| 2021-12-14 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE 1/2 CLINICAL TRIAL OF JMT601 IN THE U.S. irasia.com ↗ |
| 2021-03-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2021-03-25 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMT601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06725524 ↗ |
| Route | Intravenous | “intravenous infusion on day 1 once a week” NCT06725524 ↗ |